Clinical trials aiming to validate whether ANGPTL4 is a suitable hypoxic biomarker for RCC is currently recruiting patients and is set to finish by the end of 2025 (NCT05214885). This evidence concerns the gene ANGPTL4 and renal cell carcinoma.